

NTM-NET

NONTUBERCULOUS MYCOBACTERIA NETWORK EUROPEAN TRIALSGROUP

4th BIENNIAL MEETING

26th of September 2015

Amsterdam, The Netherlands

@ Vrije Universiteit Amsterdam

Invitation - Information - Programme



**Dear fellow NTM-NET members, clinicians and researchers
interested in NTM infections,**

we herewith invite you to the **4th biennial NTM-NET meeting** which will take place again on the day of the ERS opening ceremony in **Amsterdam** on **September 26th 2015** from **9.30 a.m.-16.00 p.m.**

We know that the date - the day after the TBnet meeting - collides with some postgraduate courses on the opening day of the ERS but we hope that again most of you can attend our meeting that takes place at the Vrije Universiteit in the main building. Seats are limited therefore we request you to register by e-mail with Cordula Ehlers @ cehlers@fz-borstel.de.

The programme again is preliminary since we actually expect suggestions and active participation, e.g. everybody that registers is welcome to contribute to the programme and is asked to suggest an own NTM-NET study idea (*please be prepared to show your current NTM-related research activities in 2-3 slides and ask yourself how it could be linked with the NTM-NET*). We will discuss the option to have NTM-PD notified after a talk of Marieke van der Werf, ECDC (*please be prepared to answer the respective questions in the programme*), share the way data are collected in the different sites (*please be prepared to contribute your own way of data collection*), and we will discuss how we can support the inclusion of NTM-patients in the EMBARC registry. Those not able to attend will find a meeting report in the members section of the meeting webpages on our home-page www.ntm-net.org. Please use this opportunity to look at the webpage, update your personal profile) and start using its options.

The meeting will officially end at 16.00 p.m., thus everybody will be able to attend the ERS opening ceremony at 17.45 p.m. at the RAI (that is 30 min. walk or two metro stops away from the Vrije Universiteit). We will have dinner at 8:30 pm (around the end of the ERS opening ceremony), details see below and on the webpage.

Concerning coffee & lunch there is no closeby restaurant that is opened on Saturdays. Therefore we organized Vietnamese food catering (20€/person including a coffee at the groundfloor coffeeshop, excluding other beverages) - another reason to register and let us know, who wants to order respective lunch.

We are looking forward to meeting you all in Amsterdam


Dirk Wagner

4th BIENNIAL NTM-NET MEETING INFORMATIONS

Registration	via email to Cordula Ehlers: cehlers@fz-borstel.de
Location name	Vrije Universiteit Main Building (Hoofdgebouw)
Location adress	Vrije Universiteit Amsterdam De Boelelaan1105, 1081 HV Amsterda
Location webpage	http://www.vu.nl/nl/index.asp
How to get there	<p>PDF-Information, Link; Metro: De Boelelaan VU, metro tram 51, tram 5, tram 16 or 24</p> 
Location map/Connection to RAI (ERS-venue)	 <p>click for larger map</p>
Room name	Rm HG-06A32
How to get there from the entrance	Go to the sixth floor and follow the signs
Telephone of Dirk Wagner	Mobile: 49 162 2852468
When does it start?	September 26th, 9:30 a.m.
When does it end?	September 26th, 4:00 p.m.
How will we have coffee	At the coffee-shop on the groundfloor, one beverage is included in the 20€.
Where will we have lunch?	At the meeting place (Vietnamese catering service, please bring 20€ in cash)
When will we have lunch?	1 p.m.
Where will we have dinner?	Surya -Indian Rest. http://www.suryarestaurant.nl/en/ Ceintuurbaan 147, 1072 GB Amsterdam Directions: see PDF-Information
When will we have dinner?	20:30 p.m.

4th BIENNIAL NTM-NET MEETING

FINAL PROGRAMME

Morning Session:

9:30-9:40	Get seated ☺	
9:40-9:45	Welcome	<i>Dirk Wagner</i>
9:45-10:30	NTM-NET Affairs	
9:45-10:15	NTM-NET 2013-2015: Activities and Development/Membership/Webpage /Twitter/NTM-Consilium/NTM-Papers/NTM Patient Talk Point	<i>Dirk Wagner</i>
10:15-10:30	NTM-NET – current and future studies	
10:15-10:30	Study updates	<i>Dirk Wagner</i>

10:30-11:00 Coffee break (*Coffee at the Coffeeshop on the ground floor*)

11:00-12:00	NTM-NET – current and future studies	
11:00-11:10	<i>CaMoMy: analysis, update, progress</i>	<i>Claire Andréjak</i>
11:10-11:30	<i>MAC-INT/Clofazimine/M. simiae</i>	<i>Jakko van Ingen</i>
11:30-11:45	<i>Radiological scoring in MAC-PD</i>	<i>Kozo Morimoto</i>
11:45-12:00	<i>Clofazimine vs. Rifampicin in treatment of naïve pMAC patients</i>	<i>Wouter Hoefsloot/Sanne Zweijpfenning</i>
12:00-13:00	NTM-NET –collaborative studies + funding : the structural problem	
12:00-12:05	<i>NTM-PD trial sites – NTM NET members participating in INS-212</i>	<i>Dirk Wagner</i>
12:05-12:10	<i>Collaboration/funding opportunities with ERS</i>	<i>Christoph Lange</i>
12:10-12:15	<i>Collaboration and funding opportunities with ESCMYC</i>	<i>Lorenzo Guglielmetti</i>
12:15-12:20	<i>Funding opportunities - example ERA-NET- what can we learn</i>	<i>Claire Andréjak</i>
12:20-12:30	<i>Studies on M.avium / M. abscessus at the RKI and possible interlinkage with NTM-NET</i>	<i>Astrid Lewin</i>
12:30-12:45	<i>How can the research of NTM-NET members linked into NTM-NET studies</i>	Open discussion <i>Please ask yourself how your own NTM-research could profit from NTM-NET participation</i>
	<i>How can we help/fuel collaborative studies under the NTM-NET label?</i>	
12:45-13:00	Time slot for new proposals/discussion	

Lunch break 1-2 p.m. - Catering service**Afternoon session****14:00-14:55 NTM-Notification**

14:00-14:10	NTM transmission	<i>Dirk Wagner</i>
14:10-14:25	Requirements and process for a disease to become a notifiable disease in the European Union	<i>Marieke van der Werf, ECDC</i>
14.25-14.50	What are the specific objectives for having NTM as a notifiable disease	Open discussion <i>(Chair MW, ML, JvI)</i> Please be prepared for this discussion and think about answers to the questions asked!
	Is having NTM as a notifiable disease the most cost-effective approach or are other approaches possible?	
	Would it be feasible for the countries?	
	What are potential case definitions?	
	What species should be included?	
14:50-14:55	Foundation of a working group: Implementation of a common surveillance system on NTM isolates from respiratory secretions	
15:00-15:45	Embarc with EMBARC – NTM registry	
15:00-15:10	Update on the NTM-inclusion of the US Non-CF Bronchiectasis registry	<i>Tim Aksamith</i>
15:10-15:20	The EMBARC-registry	<i>Felix Ringshausen</i>
15:20-15:30	What data are currently collected in Europe and how?	<i>Claire Andrejak, Marc Lipman, Jakko van Ingen</i>
15:30-15:55	How and what to add to the registry, how to support	Open discussion <i>(Chair TA/FR)</i>
15:55-16:00	Concluding remarks	<i>Dirk Wagner</i>

16:00-17:45 / 20:30 **Coffee or Beer break - Heineken Experience or at the RAI (to be discussed)**

ERS opening ceremony from 17:45 (for those who wish to attend)

NTM-NET Dinner / Get together (some may have eaten at the opening ceremony) from 20:30 pm **Surya Amsterdam,**
<http://www.suryarestaurant.nl/en/>,
 Ceintuurbaan 147, 1072 GB Amsterdam

Evaluation of the meeting: <https://my.surveypal.com/4th-biennial-NTM-NET-Meeting-2015>



2.5.3. *Zoonoses (other than in 2.4)*

Brucellosis
Echinococcosis
Rabies

2.5.4. *Serious imported diseases*

Cholera
Malaria
Plague
Viral haemorrhagic fevers

3. **SPECIAL HEALTH ISSUES**

3.1. **Nosocomial infections**

3.2. **Antimicrobial resistance**

ANNEX II

Criteria for selection of communicable diseases of special areas to be covered by epidemiological surveillance within the network.

1. Diseases that cause, or have the potential to cause, significant morbidity and/or mortality across the Community, especially where the prevention of the diseases requires a global approach to coordination.
 2. Diseases where the exchange of information may provide early warning of threats to public health.
 3. Rare and serious diseases which would not be recognised at national level and where the pooling of data would allow hypothesis generation from a wider knowledge base.
 4. Diseases for which effective preventive measures are available with a protective health gain.
 5. Diseases for which a comparison by Member States would contribute to the evaluation of national and Community programmes.
-